These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 35512745)
1. Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19. Hong JY; Ko JH; Yang J; Ha S; Nham E; Huh K; Cho SY; Kang CI; Chung DR; Baek JY; Sohn YM; Park HJ; Lee B; Huh HJ; Kang ES; Suh GY; Chung CR; Peck KR Yonsei Med J; 2022 May; 63(5):430-439. PubMed ID: 35512745 [TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770 [TBL] [Abstract][Full Text] [Related]
3. Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. Abbasian L; Toroghi N; Rahmani H; Khalili H; Hasannezhad M; Ghiasvand F; Jafari S; Salehi M; Salahshour F; Azadbakhsh Kanaf Gorabi M; Alizade F; Ghaderkhani S; Nakhostin M Int Immunopharmacol; 2022 Jun; 107():108689. PubMed ID: 35313272 [TBL] [Abstract][Full Text] [Related]
5. Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab. Sandhu G; Piraino ST; Piticaru J Am J Ther; 2022 May-Jun 01; 29(3):e275-e278. PubMed ID: 35249968 [TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C; J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677 [TBL] [Abstract][Full Text] [Related]
7. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial. Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328 [TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
9. Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality. Sinha P; Linas BP Clin Infect Dis; 2021 Dec; 73(11):2116-2118. PubMed ID: 33956936 [TBL] [Abstract][Full Text] [Related]
10. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. Moes DJAR; van Westerloo DJ; Arend SM; Swen JJ; de Vries A; Guchelaar HJ; Joosten SA; de Boer MGJ; van Gelder T; van Paassen J Clin Pharmacokinet; 2022 Feb; 61(2):231-247. PubMed ID: 34633645 [TBL] [Abstract][Full Text] [Related]
12. Different COVID-19 treatments' impact on hospital length of stay. Iwamoto S; Muhar BK; Chen H; Chu H; Johnstone M; Sidhu A; Chu H; Fischer J; Chu G Eur J Med Res; 2023 Jul; 28(1):218. PubMed ID: 37400927 [TBL] [Abstract][Full Text] [Related]
13. C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. Camon AM; Alonso R; Muñoz FJ; Cardozo C; Bernal-Maurandi J; Albiach L; Agüero D; Marcos MA; Ambrosioni J; Bodro M; Chumbita M; De la Mora L; Garcia-Pouton N; Dueñas G; Hernandez-Meneses M; Inciarte A; Cuesta G; Meira F; Morata L; Puerta-Alcalde P; Rico V; Herrera S; Tuset M; Castro P; Prieto-González S; Almuedo A; Muñoz J; Mensa J; Sanjuan G; Nicolas JM; Del Rio A; Vila J; García F; Martínez JA; Garcia-Vidal C; Soriano A; Sci Rep; 2022 Mar; 12(1):5250. PubMed ID: 35347166 [TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of tocilizumab vs standard care in patients with severe COVID-19-related pneumonia: a retrospective cohort study utilizing registry data as a synthetic control. Uemura Y; Ozaki R; Shinozaki T; Ohtsu H; Shimizu Y; Izumi K; Saito S; Matsunaga N; Ohmagari N BMC Infect Dis; 2023 Dec; 23(1):849. PubMed ID: 38049729 [TBL] [Abstract][Full Text] [Related]
15. Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk. Brosnahan SB; Chen XJC; Chung J; Altshuler D; Islam S; Thomas SV; Winner MD; Greco AA; Divers J; Spiegler P; Sterman DH; Parnia S Ann Pharmacother; 2022 Mar; 56(3):237-244. PubMed ID: 34180274 [TBL] [Abstract][Full Text] [Related]
16. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514 [TBL] [Abstract][Full Text] [Related]
18. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707 [TBL] [Abstract][Full Text] [Related]
19. Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. Sánchez-Montalvá A; Sellarés-Nadal J; Espinosa-Pereiro J; Fernández-Hidalgo N; Pérez-Hoyos S; Salvador F; Durà X; Miarons M; Antón A; Eremiev-Eremiev S; Sempere-González A; Monforte-Pallarés A; Bosch-Nicolau P; Augustin S; Sampol J; Guillén-Del-Castillo A; Almirante B Med Clin (Barc); 2022 Jun; 158(11):509-518. PubMed ID: 34544604 [TBL] [Abstract][Full Text] [Related]
20. Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients. Rutgers A; Westerweel PE; van der Holt B; Postma S; van Vonderen MGA; Piersma DP; Postma D; van den Berge M; Jong E; de Vries M; van der Burg L; Huugen D; van der Poel M; Kampschreur LM; Nijland M; Strijbos JH; Tamminga M; Mutsaers PGNJ; Schol-Gelok S; Dijkstra-Tiekstra M; Sidorenkov G; Vincenten J; van Geffen WH; Knoester M; Kosterink J; Gans R; Stegeman C; Huls G; van Meerten T PLoS One; 2022; 17(8):e0271807. PubMed ID: 35960720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]